The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
DBV Technologies shifts plans for Goldman Sachs healthcare conference appearance
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jun 9, 7:22 AM EDT

DBV Technologies shifts plans for Goldman Sachs healthcare conference appearance

The late-stage allergy drug developer said its CEO will miss a previously scheduled fireside chat but will still meet investors one-on-one during the Goldman Sachs 47th Annual Global Healthcare Conference in Miami.

By The Apex Times Newsroom2 min readAI-assisted Apex article

DBV Technologies said it has revised its participation in the Goldman Sachs 47th Annual Global Healthcare Conference, adjusting scheduled remarks by CEO Daniel Tassé. The company, headquartered in Châtillon, France, announced on June 9, 2026 that management would still take part in one-on-one investor meetings at the conference in Miami, but Tassé would not be available for a fireside chat that had been planned for the same day.

In a statement accompanying the change, DBV Technologies said Tassé’s absence is due to an unavoidable disruption to planned travel. The company did not specify the nature of the travel issue or provide an updated date or time for any replacement fireside chat.

DBV Technologies is a late-stage biopharmaceutical company focused on food allergy and other immunologic conditions with significant unmet medical need. Its core technology is VIASKIN, an “epicutaneous immunotherapy” approach, delivered through a patch placed on the skin. The company characterized VIASKIN as designed to introduce microgram amounts of a biologically active treatment aimed at retraining an immune response that causes allergies and a range of symptoms from mild reactions to life-threatening anaphylaxis.

The patch-based strategy is being developed to address food allergies, which DBV Technologies said affect millions of people, including children. The company’s conference update did not tie the revised appearance to any new clinical results, nor did it add details about upcoming regulatory steps or trial timelines.

By participating in one-on-one meetings, DBV Technologies’ management can still meet investors in a format often used during healthcare conferences to discuss strategy, pipeline progress, and near-term catalysts. For the Goldman event itself, the statement framed the agenda change as a logistical one rather than a change in business priorities or guidance.

For Goldman Sachs, the annual global healthcare conference is a recurring venue where management teams from healthcare and life sciences companies meet investors. DBV’s revision is consistent with the way conferences often require last-minute schedule adjustments, particularly for executive availability and travel coordination.

The company’s announcement also did not disclose whether any other member of management would cover the content originally expected in the fireside chat, such as pipeline updates or development milestones. It likewise did not indicate whether an alternative session format, written follow-up, or rebooking with investors was planned.

Investors and observers may watch for further clarification on how DBV Technologies will communicate the topics planned for Tassé’s fireside chat, as well as any next disclosures connected to its VIASKIN patch program. The immediate takeaway from the conference update is that DBV will remain present for investor meetings, but the company is temporarily adjusting who speaks publicly during the scheduled panel segment.

Why It Matters

  • Executive availability is a practical factor at major healthcare conferences, and missed sessions can affect how quickly investors receive verbal pipeline updates.
  • DBV Technologies’ continued one-on-one meetings suggest it still intends to maintain direct investor engagement during the event window.
  • Because the announcement did not cite new clinical or regulatory developments, the change appears logistical rather than indicating a shift in the program’s scientific agenda.

Sources

Key Facts

  • DBV Technologies said management will participate in one-on-one investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 in Miami, Florida.
  • CEO Daniel Tassé will not be available for a previously scheduled fireside chat at the conference.
  • DBV Technologies attributed Tassé’s absence to an unavoidable disruption in planned travel.
  • DBV Technologies described itself as a late-stage biopharmaceutical company developing VIASKIN patch-based epicutaneous immunotherapy for food allergies and other immunologic conditions.
  • The company did not provide details on a replacement fireside chat or additional public remarks.

Finance Related

DBV Technologies shifts plans for Goldman Sachs healthcare conference appearance | The Apex Times